About the project
The published results of the Prostate MRI Imaging Study (PROMIS) in the Lancet have shown that giving a man a multi-parametric Magnetic Resonance Imaging (mpMRI) scan before a biopsy can radically improve the accuracy of the diagnostic process for prostate cancer.
Here at Prostate Cancer UK, we believe mpMRI before biopsy offers the potential for a step-change in prostate cancer diagnosis. Results of the PROMIS trial have shown mpMRI before biopsy to be significantly better at identifying clinically significant prostate cancer compared to TRUS (trans-rectal ultrasound) biopsy, and can also reduce the number of men having biopsies unnecessarily by a quarter (27%) because the scan will only pick up cancers which could cause men harm and need further tests.
To coincide with the publication of the PROMIS trial, we are releasing Freedom of Information request data which highlights the challenges that must addressed as a priority if this game-changing diagnostic technique is to reach all eligible men in the near future. The specific challenges include having enough of the right scanners in the right places, training and increasing capacity of the radiologist and radiographer workforce, ensuring uniformity and quality of method and willingness to change.
We’ll be working to ensure that prostate mpMRI before biopsy becomes a priority for early diagnosis ambitions in each of the UK’s nations and want to work collaboratively with each national health service to establish ways to overcome the scanner capacity and resource challenges that we have identified.